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ABSTRACT
Objectives: We report the case of a twin pregnancy with a partial hydatidiform mole and a coexistent live fetus diagnosed 
in a 28-year-old primipara at 15 weeks of gestation and discuss the problems associated with the ultrasound diagnosis, 
histopathological examination of molar tissue samples and treatment.
Material and methods: A systematic research of the literature was conducted in PubMed database and Cochrane Library, 
including case reports and case series. A new case was also discussed. We collected data regarding the patient’s serum 
human chorionic gonadotropin (hCG) level, initial symptoms, diagnosis and treatment.
Results: Most of the cases reported in the literature are those of a multiple pregnancy with complete hydatidiform 
mole (CHM) and a coexistent live fetus. The coexistence of a twin pregnancy with partial hydatidiform mole (PHM) 
and a live fetus in two separate amniotic sacs is extremely rare as a partial mole usually causes miscarriage of ear-
ly pregnancy. Ultrasound is an important diagnostic tool, but the correct diagnosis is made only in 68% of cases. 
With further histological assessment of molar specimens and biochemical assays, the rates of correct early diagnoses should 
increase contributing to early therapeutic decisions and fewer adverse events. 
Conclusions: The diagnosis, management, and monitoring of this condition will remain challenging because of its rarity. 
Because of that, all cases of a suspected multiple pregnancy with a hydatidiform mole and a coexistent live fetus should be 
referred to and managed at a tertiary center which specializes in the diagnosis and treatment of gestational trophoblastic 
disease.
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INTRODUCTION
The coexistence of a hydatidiform mole with a normal 
fetus is extremely rare with an incidence of 1/20  000 to 
1/100,000 pregnancies [1–4]. In most cases, this is a com-
plete hydatidiform mole (CHM). Partial hydatidiform mole 
(PHM) coexistent with a live fetus, in two separate amniotic 
sacs, is even less frequent since a partial molar pregnancy 
usually ends in early intrauterine death and miscarriage [5]. 
Diagnosis is by ultrasound, mostly in the second trimester, 
usually between 12 and 15 weeks [1, 3]. Even with advanced 
ultrasound technologies, correct diagnosis is made in ap-
proximately 68% of cases and first-trimester diagnoses are 
rare. Assessment of human chorionic gonadotropin (hCG) 
levels are less reliable in a multiple pregnancy. Magnetic 
resonance imaging (MRI) is useful in the diagnosis of a molar 
pregnancy with a coexisting live fetus as it visualizes two 
amniotic sacs and a separate normal placenta and addi-
tionally allows assessment for myometrial infiltration and 
parametrial involvement [6]. 
There are three possible variations of a twin molar 
pregnancy with a coexistent live fetus: 1. A dizygotic twin 
pregnancy with a complete mole and a live fetus of diploid 
karyotype; 2. A dizygotic twin pregnancy with a partial 
mole and a live diploid fetus in two separate amniotic sacs; 
3. A monozygotic twin pregnancy with a partial mole and 
a live triploid fetus in a second amniotic sac [5]. 
This paper presents a case of a twin pregnancy with 
a partial hydatidiform mole and a coexistent live fetus and 
discusses problems associated with the ultrasound diagno-
sis, histopathological examination of molar tissue samples, 
and treatment.
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Case report
A 28-year-old primipara at 15 weeks of twin pregnancy 
was referred to the 1st Department of Obstetrics and Gy-
necology, Medical University of Warsaw from an antenatal 
clinic at her local hospital with a suspected hydatidiform 
mole and a coexistent live fetus in a second amniotic sac. 
Pre-referral medical and obstetric history
The age at menarche 13 years. Before pregnancy, the 
patient received thyroid hormone replacement therapy 
for hypothyroidism. She had been trying to conceive for 
two years and ovulation induction was used in the last four 
cycles before conceiving. At 12 weeks of gestation, she was 
admitted to hospital with ovarian hyperstimulation syn-
drome. An ultrasound examination showed in the uterine 
cavity one live fetus whose measurements were consist-
ent with gestational age of 11 weeks and five days. Seen 
behind the uterus, the ovaries were enlarged (the right 
measured 94 × 57 × 40 mm and the left 94 × 54 × 41 mm) 
with numerous follicles. There was some free fluid behind 
the uterus and between the coils of the intestine. There 
were no abnormalities detected on an abdominal ultra-
sound. The patient was prescribed anticoagulants and on 
day five was discharged home in good general condition. 
A first-trimester ultrasound performed one day later showed 
a normal development of a singleton pregnancy. The ovaries 
were enlarged as previously. After one week, the patient was 
readmitted to hospital for vaginal spotting. An ultrasound 
examination confirmed fetal cardiac activity and detected 
over the internal os a haematoma measuring 26 × 6 mm. 
A threatened miscarriage was diagnosed. The patient was 
prescribed progestins and antihaemorrhagic medication 
with a follow-up visit in 10 days when she was seen by 
her obstetrician. An ultrasound examination ten days later 
detected in the posterior uterine wall a 75 × 148 mm lesion 
with numerous fluid-filled spaces. The serum hCG level was 
over 1000,000 mIU/mL. The patient was referred to our 
Department.
On admission
Good general condition. On speculum examina-
tion a slight cervical bleeding. The size of the uterus cor-
responded with 25 weeks of gestation. Blood pressure 
140/80, pulse 112/min, temperature 37.3°C. An ultrasound 
examination detected in the uterine cavity a live fetus 
131g in weight, normal placenta and a cystic-solid lesion 
measuring 118 × 77 × 70 mm. The right ovary measured 
100 × 60 × 58 mm and the left ovary 101 × 55 × 53 mm. 
Blood tests: RBC 3.49 million/mm3, Hb 11 g/dL, Ht 30.2%, 
WBC 8,600/mm3, PLT 289 000/mm3, hCG 1 601 660 mIU/mL, 
ALT 77 U/L, LDH 327 U/L, creatinine 0.62 mg/dL, potassium 
4.2 mmol/L, sodium 136 mmol/L, TSH < 0.005 µIU/L, free 
FT3 7.61 pg/mL, free FT4 2.85 ng/dL, anti-TSH receptor an-
tibodies < 0.8 IU/L, anti-TPO antibodies 1192.8 U/mL, INR 
1.12, prothrombin time 12.4 s, prothrombin ratio (PR) 90%.
A multiple pregnancy with a CHM and a coexistent 
live fetus was diagnosed. In view of exceedingly high hCG 
levels, clinical hyperthyroidism confirmed by laboratory 
investigations and features of liver injury, the prognosis for 
pregnancy outcome was considered to be poor and the 
pregnancy threatened the mother’s life and health. Termi-
nation of pregnancy was planned after prior institution of 
beta-blockers. The patient gave her informed written con-
sent to surgical uterine evacuation, uterine curettage and 
hysterectomy, if necessary. The procedure was performed 
under general anaesthesia with antibiotic prophylaxis. The 
cervix of the uterus was dilated with Hegar dilators up to 
No 20. The molar tissue was aspirated under ultrasound 
guidance and next the fetus and placenta were removed. 
As the bleeding continued, curettage of the uterine cavity 
was performed, and oxytocin was given to induce haemo-
stasis. The blood loss was estimated at ca. 2,000 mL. On the 
first postoperative day, the patient was well with normal 
vital signs. The uterus was well contracted with a moder-
ate vaginal bleeding. Blood tests: RBC 3.05 million/mm3, 
Hb 9.8 g/dL, Ht 26.2%, WBC 6 900/mm3, PLT 232 000/mm3, 
hCG 598 350 mIU/mL, ALT 53 U/L, AST 34 U/L, LDH 318 U/L. 
Lactation was suppressed. On the third postoperative day 
a slight vaginal bleeding persisted, and the patient had no 
complaints. On pelvic examination the uterus remained 
well contracted and painless. An ultrasound examination 
showed an empty uterus and the same appearance of the 
ovaries as on previous scans. The patient was discharged 
home in good general condition and advised to have hCG 
levels monitored every seven days (on discharge the serum 
hCG was 160 140 mIU/mL) and to continue medication for 
lactation suppression and beta-blockers.
Three weeks later the patient collected the histopathol-
ogy report of a complete hydatidiform mole. The hCG was 
6,660 mIU/mL and close to the level measured seven days 
earlier (6,672 mML). As the hCG levels failed to decrease, the 
patient was referred to her local oncology hospital where 
she was followed-up at one week intervals.
After a 3-month follow up, the patient was referred 
to the Center for Gestational Trophoblastic Disease at the 
Institute of Mother and Child. Based on the biochemical 
criteria (the plateau of hCG for the last four measurements) 
gestational trophoblastic neoplasia (GTN) was diagnosed. 
The molar specimens were re-examined at the Institute’s 
Pathology Laboratory with the following findings: decidual 
and placental tissue fragments with features of oedematous 
degeneration of avascular villi, cistern-like villi present, mild 
focal atypia and partial degeneration of the trophoblast 
which corresponded with a partial hydatidiform mole. 
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Table 1. Recommended single-agent chemotherapy regimens for 
gestational trophoblastic disease
MTX 0.4 mg/kg IM. or IV, on days 1, 2, 3, 4 and 5, repeat every 14 days
MTX 50 mg/m2 IM, repeat every 7 days
Dactinomycin 1.25 mg/m2 IV, repeat every 14 days
Dactinomycin 12 µg/kg IV on days 1, 2, 3, 4 and 5, repeat every 14 days
MTX 1 mg/kg (up to 70 mg) IM or IV, on days 1, 3, 5 and 7, repeat 
every 14 days + FA 0.1 mg/kg IM or IV, on days 2, 4, 6 and 8, repeat 
every 14 days
MTX 50 mg IM, on days 1, 3, 5 and 7, repeat every 14 days + FA 
15 mg IM or IV, 30h after the start of MTX administration
FA — folinic acid; IM — intramuscular; IV — intravenous; MTX — methotrexate
As there were two different histopathological diagnoses 
(complete vs partial hydatidiform mole), immunohisto-
chemical staining for p57KIP2 was additionally performed 
which was positive in the trophoblastic cells and confirmed 
the diagnosis of a partial hydatidiform mole.
A transvaginal ultrasound examination visualized an an-
teverted uterus with the AP diameter of 54 mm. The myome-
trial and endometrial echogenicity was homogenous, but in 
the posterior wall, adjacent to the internal os, a hyperecho-
genic lesion with visible vasculature, measuring 6 × 5 × 7 mm 
was detected. Both ovaries were normal. On Doppler ultra-
sonography the pulsatility index (PI) was 1.86 for the right 
uterine artery and 2.45 for the left uterine artery. There were 
no abnormalities detected on a chest x-ray.
The patient was classified as low-risk according to the 
FIGO criteria (score 2; antecedent pregnancy — abortion, 
score 1, pretreatment hCG between 103–104 mIU/L, score 1). 
MTX-FA (methotrexate/folinic acid) 8-day regimen, repeated 
every 2 weeks was prescribed (Tab. 1). The patient received 
chemotherapy in a total of 18 courses, including 3 courses 
of consolidation therapy. For the patient’s convenience the 
treatment was administered in collaboration with her local 
hospital. The chemotherapy was well tolerated and occa-
sional burning sensation in the oral cavity was relieved by 
symptomatic treatment, there were no cycle delays.
At present, the patient remains under close observa-
tion. The levels of hCG were monitored every 4 weeks for 
6 months and then every 8 weeks for 12 months. The patient 
was advised to use effective contraception during that time. 
DISCUSSION
The article presents difficulties in the diagnosis and 
treatment of a twin molar pregnancy with a coexistent nor-
mal live fetus. In the reported case, a molar pregnancy was 
first suspected as late as 15 weeks of gestation. Although the 
overall clinical and morphology picture was characteristic 
of a CHM, a PHM was identified by immunohistochemistry. 
At present, an ultrasound examination is the main imag-
ing tool used to establish the diagnosis. The ‘Swiss-cheese 
pattern’ placenta separate from a normal-appearing pla-
centa is pathognomonic [6]. When the normal appearance 
of the placenta is not visualized, a complete hydatidiform 
mole with a coexistent live fetus (CHMCF) may be misdiag-
nosed as a singleton pregnancy with a partial mole and a live 
fetus in one amniotic sac. Since the prognosis for pregnancy 
outcome is different in each case, visualization of a normal 
placenta often adjacent to a large molar placenta is of key 
importance for the correct diagnosis [7, 8]. PHM is more 
difficult to diagnose than CHM even in a singleton preg-
nancy due to the absence of the characteristic ultrasound 
features. The differential diagnosis should include a subcho-
rionic haematoma, with a similar cystic-solid appearance 
and a mild trophoblast pathology of placental mesenchymal 
dysplasia coexistent with Beckwith-Wiedemann syndrome 
in the fetus [1, 2, 5].
Standard pathomorphologic assessment includes hae-
matoxylin and eosin (H&E) staining and distinguishing the 
type of hydatidiform mole by morphology. In each case of 
a molar pregnancy a second opinion should be sought from 
another expert of pathomorphology laboratory, as we did 
in the reported case. Immunohistochemical staining for 
the protein p57KIP2, which is the product of the CDKNIC 
gene, is a reliable diagnostic tool. As CDKNIC is paternally 
imprinted and maternally expressed, the p57 staining is 
absent in CHM which lacks a maternal genome [9]. In the 
reported case, CHM was initially diagnosed by morphology 
alone and after reassessment of the molar tissue specimens 
at a tertiary medical center, the final diagnosis of PHM was 
established, confirmed by positive staining for p57KIP2.
The coexistence of a molar pregnancy and a live normal 
fetus carries a risk of severe fetal and maternal complica-
tions. The most common maternal complications include se-
vere haemorrhage leading to anaemia, severe preeclampsia, 
hyperthyroidism and thromboembolic disorders [1, 4–6, 8]. 
Also common are such events as fetal growth retardation, in-
trauterine death, miscarriage or premature birth [1, 4, 7, 10]. 
Most of the cases reported in the literature are those of 
a multiple pregnancy with CHM and a coexistent live fe-
tus. The coexistence of a multiple pregnancy with PHM and 
a live fetus in two separate amniotic sacs is extremely rare as 
a partial mole usually causes miscarriage of early pregnancy 
(10–20% of early spontaneous abortions) [3, 11].
The reported patient had severe hyperthyroidism and 
features of liver injury which were indications for pregnancy 
termination. In the past, the diagnosis of a molar pregnancy 
with a coexistent live fetus was an indication for an immedi-
ate therapeutic termination [4, 8]. Now, when a normal fetal 
development is confirmed by ultrasound and there are no 
maternal complications, analysis of the fetal karyotype is 
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recommended. Women who decide to proceed with their 
pregnancy should be aware that the chances of a successful 
outcome are approximately 40% [1, 2, 6]. A conservative ap-
proach is possible under close monitoring and when there 
are no maternal complications [3, 4, 6]. Decreasing hCG 
levels and absence of maternal complications are good pre-
dictors of a successful pregnancy outcome [12]. Abnormal 
fetal anatomy visualized by ultrasound or abnormal fetal 
karyotype are indications for termination. The risk for GTN 
in cases of a molar pregnancy with a coexistent live fetus 
ranges from 16 to 50% [1]. The development of invasive 
moles, choriocarcinomas or placental-site trophoblastic 
tumors has been reported [6]. The patient here reported 
developed GTN although she was finally diagnosed with 
PHM. The risk of GTN after surgical evacuation of CHM with 
a live fetus is significantly higher than the risk associated 
with evacuation of PHM in a multiple pregnancy (10–28% 
vs 3–5%) [5]. It is still unclear whether the continuation 
of pregnancy increases the risk for GTN [8]. According to 
many authors the duration of pregnancy has no effect on 
the development of GTN [1, 2, 4, 6, 13]. Also, there is no 
agreement concerning a more frequent occurrence of GTN 
after a twin pregnancy with CHM compared to a singleton 
pregnancy. Some authors found no differences in the inci-
dence of GTN after a singleton complete molar pregnancy 
vs multiple molar pregnancy [2, 14]. Steller et al., however, 
observed the development of GTN in as many as 55% of 
women with a molar pregnancy with a coexistent fetus [15]. 
A national collaborative study in Japan found a considerably 
higher rate of subsequent GTN development in patients with 
CHMCF. Heavy vaginal bleeding and severe preeclampsia are 
substantial risk factors for subsequent GTN [13].
The patient we report had ovulation induction for the 
last four cycles before conceiving. Some authors find a high-
er risk for twin molar pregnancies subsequent to ovulation 
induction [5]. In a case series reported by Giorgione et al. [1] 
one third of the patients had had ovulation induction. It is 
suspected that ovulation induction may be associated with 
the appearance of ova without nuclei and thus increase the 
risk of molar pregnancy [16]. 
The method of termination if the woman does not 
wish to proceed with her pregnancy or maternal medical 
conditions exclude the use of a conservative approach is 
another dilemma. Most controversial is the management 
of a molar pregnancy in the second trimester. Since the 
pregnancy is advanced, termination by vaginal evacuation 
may be associated with massive bleeding. When choosing 
hysterotomy abortion, extreme fetal immaturity must be 
taken into consideration. In the case here reported, the 
cervix was mechanically dilated, and the uterus evacuated, 
with an estimated blood loss of 2 000 mL. Vaisbuch et al. 
used a similar procedure at 16 weeks gestation in a patient 
with early onset severe preeclampsia and thyreotoxicosis 
[8]. Braga et al. reported termination by hysterotomy of 
a pregnancy with CHMCF at 15 weeks gestation, due to the 
worsening of the mother’s clinical condition with hCG levels 
of 1 881 508 mIU/mL [7]. Braga commented that uterine 
evacuation by aspiration is not possible after the 12th week 
of gestation due to the presence of a fetal skeleton. Also, 
the use of misoprostol is contraindicated as it may increase 
the likelihood of massive pulmonary thromboplastic em-
bolization. After the first trimester, laparotomy and uterine 
evacuation by hysterotomy may be considered, especially 
when there are risk factors for adverse outcomes [7].  Close 
monitoring of hCG levels is mandatory after uterine evacu-
ation of a molar pregnancy with a coexistent live fetus as it 
is after termination of a singleton pregnancy. 
Differentiating of a complete mole from a partial mole 
is particularly important for choosing sufficient length of 
follow-up. With partial moles the risk of subsequent GTN is 
several-fold lower [17]. When a partial mole in a singleton 
pregnancy is evacuated, the patient needs to remain under 
observation for 4 weeks after the normalization of hCG. With 
a complete mole, hCG levels are monitored for up to 6 to 
12 months, depending on the time of hCG normalization, 
within 8 weeks following evacuation or later than 8 weeks 
after evacuation.
Before starting the treatment of GTN, imaging studies 
should be performed to assess how advanced GTN is and 
to estimate the probability of single-agent chemotherapy 
failure. The patient here reported was classified as low-risk 
according to the FIGO criteria (score 2). MTX/FA 8-day regi-
men at a stable dose 50 mg/15mg was prescribed in view of 
its effectiveness and a manageable toxicity profile. FA given 
30 h after MTX administration reduces MTX-associated hae-
matological toxicity, but the time schedule of dosing must 
be strictly observed in order not to decrease the therapeutic 
effectiveness of MTX. Dactinomycin-based regimens have 
a less favourable adverse reaction profile with a higher 
incidence of nausea, vomiting and hair loss. 
The hGG level was measured before each course of 
chemotherapy to assess response to treatment. During 
chemotherapy there is no need for imaging studies when 
the hCG levels gradually decrease. MTX/FA regimen was 
continued until hCG normalization and followed by three 
consolidation courses. 
One important issue we encountered, was the correct 
assessment of hCG normalization which depends on the 
sensitivity of the laboratory test used. Several molecular 
variants of hCG present in serum include:
•	 intact hCG
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•	 nicked free β-subunit
•	 β- subunit core fragment
In GTN, the percent ratios of free hCG β-subunit to total 
hCG vary depending on the degree of trophoblast differ-
entiation from approximately 1% in PHM to 2.4% in CHM 
to 9% in choriocarcinoma. Carbohydrates account for ap-
proximately 30% of hCG mass and carbohydrate structure 
changes when they are synthesized by cancer cells. When 
the peptide chain is nicked, there is loss of biological activity 
and changes in the antigenicity of hCG. That is why a routine 
pregnancy test is less sensitive than the assays specifically 
designed to monitor hCG-secreting cancers. The use of hCG 
assays standardized to the World Health Organization (WHO) 
Fourth International Standard is recommended to minimize 
the risk of false negatives [18].
In the case here described, the hCG level before the 
13th course of chemotherapy, measured outside the ref-
erence center, was 4.3 mIU/mL, which was considered as 
a negative result by the local center. The hCG level measured 
14 days later at the reference center was 3.8 mIU/mL with 
the cut-off value of 1 mIU/mL. A shared treatment decision 
made by the patient and her doctor was to continue regular 
hCG measurements but using a more sensitive assay and 
to proceed with chemotherapy until hCG levels returned 
to normal, which was observed before the 16th course of 
chemotherapy. In line with the current recommendations 
for patients with low-risk GTN, three courses of consolida-
tion chemotherapy were administered. A study from the 
UK and The Netherlands found two-fold lower relapse rates 
in low-risk GTN patients treated with three consolidation 
courses compared to patients treated with two consoli-
dation courses [19]. After completing chemotherapy the 
patient must remain under observation and the hCG levels 
should be monitored with the measurements every month 
for six months after normalization, then every two months 
for up to 12 months post-normalization and finally every six 
months for up to 5 years. Patients are advised to use highly 
effective contraception in the first 12 months. In low-risk 
GTN the prognosis is good, there is a minor risk of recurrence 
and the complete remission rate is nearly 100%.
To sum up, a multiple pregnancy complicated by a hy-
datidiform mole carries a risk of severe maternal and fetal 
adverse events. It should be emphasized that in the reported 
case the ultrasound scans and the clinical presentation 
strongly suggested the presence of a complete mole with 
a coexistent live fetus, but the diagnosis of a partial mole 
was ultimately made histologically. With further advances in 
ultrasound technologies, histological assessment of molar 
specimens and biochemical assays, the rates of correct early 
diagnoses should increase contributing to early therapeu-
tic decisions and fewer adverse events. Considering their 
exceptionally low frequency, all cases of a suspected mul-
tiple pregnancy with a hydatidiform mole and a coexistent 
live fetus should be referred to and managed at a tertiary 
center which specializes in the diagnosis and treatment of 
gestational trophoblastic disease.
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